Skip to main navigation Skip to search Skip to main content

Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: Case finding through the emerging infections network

Research output: Contribution to journalArticlepeer-review

Abstract

We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor compounds and other novel targeted therapies. Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context.

Original languageEnglish (US)
Pages (from-to)1738-1740
Number of pages3
JournalClinical Infectious Diseases
Volume46
Issue number11
DOIs
StatePublished - Jun 1 2008

Funding

FundersFunder number
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of HealthU50CI000358

    ASJC Scopus subject areas

    • Microbiology (medical)
    • Infectious Diseases

    Fingerprint

    Dive into the research topics of 'Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: Case finding through the emerging infections network'. Together they form a unique fingerprint.

    Cite this